These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 34446853)
1. Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial. Malladi R; Ahmed I; McIlroy G; Dignan FL; Protheroe R; Jackson A; Moss P; Nunnick J; Siddique S; Bishop R; Elhaneid M; Hodgkinson A; Craddock C Bone Marrow Transplant; 2021 Dec; 56(12):2948-2955. PubMed ID: 34446853 [TBL] [Abstract][Full Text] [Related]
2. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study. Kim N; Min GJ; Im KI; Nam YS; Song Y; Lee JS; Oh EJ; Chung NG; Jeon YW; Lee JW; Cho SG Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928436 [TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701 [TBL] [Abstract][Full Text] [Related]
4. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD. Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214 [TBL] [Abstract][Full Text] [Related]
5. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584 [TBL] [Abstract][Full Text] [Related]
6. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483 [TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484 [TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841 [TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. Belina ME; Driscoll TA; Blanchard SK; Cardones AR Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308 [TBL] [Abstract][Full Text] [Related]
14. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924 [TBL] [Abstract][Full Text] [Related]
15. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349 [TBL] [Abstract][Full Text] [Related]
20. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y Front Immunol; 2021; 12():673636. PubMed ID: 34276662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]